Physician profile
Fardad Mobin
NPI 1659316156
$2,444.98
in general payments reported to CMS, 2019-2025
15 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $159 · 2021: $312 · 2022: $80.62 · 2023: $190 · 2024: $164 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,169 · Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,168.89 |
| Food and Beverage | $577.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,438.06 | 2022-2025 | Proclaim, Infinity, Eterna |
| Sientra, INC. | $242.23 | 2021 | |
| Integra Lifesciences Corporation | $158.46 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Stryker Corporation | $140.92 | 2020 | |
| Kyocera Medical Technologies, INC. | $125.15 | 2019-2024 | |
| Hologic Sales and Service, LLC | $93.69 | 2019 | |
| Nevro Corp. | $51.35 | 2020-2024 | Senza |
| Si-Bone, INC. | $44.55 | 2021-2022 | |
| Spinal Elements, INC. | $31.82 | 2021 | |
| Emd Serono, INC. | $22.83 | 2019 | |
| Incyte Corporation | $21.25 | 2021 | |
| Saluda Medical Americas, INC. | $20.66 | 2024 | Evoke |
| Electronic Waveform Lab, INC. | $20.33 | 2022 | |
| Medacta USA, INC. | $18.56 | 2023 | Must |
| Biotronik Nro, INC. | $15.12 | 2024 | Prospera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fardad Mobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.